Morales-Cabeza Cristina, Roa-Medellín Dasha, Torrado Inés, De Barrio Manuel, Fernández-Álvarez Carmen, Montes-Aceñero Juan Francisco, De La Riva Inmaculada, Prieto-García Alicia
Allergy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Quality Service, Radiology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Ann Allergy Asthma Immunol. 2017 Dec;119(6):553-557. doi: 10.1016/j.anai.2017.08.014. Epub 2017 Oct 7.
Immediate hypersensitivity reactions (IHRs) to iodinated contrast media (ICMs) remain a common clinical concern. Positive skin test and basophil activation test results suggest a specific IgE-mediated mechanism in some cases. Skin test and controlled challenge test (CCT) are useful to manage these patients.
To study clinical and allergologic features of IHRs to ICMs in a Spanish tertiary hospital during a 7-year period.
Demographic and clinical data concerning the reaction were recorded. Patients treated at the Allergy Department of Hospital General Universitario Gregorio Marañón, Madrid, Spain, underwent skin tests. In those with positive results, CCTs with an alternative skin-test-negative ICM was performed. Global reaction rate was calculated and compared for each ICM.
A total of 342 reactions occurred in 329 patients. Cutaneous symptoms were the most common (87.7%). A total of 196 patients underwent an allergy workup, 15 (7.6%) of whom had positive skin test results. Reactions were more severe in patients with positive vs negative skin test results (grade 1, 46.7% vs 73.6%; grade 2, 33.3% vs 20.9%; grade 3, 20% vs 5.46%; P < .05). Three patients had cross-reactivity to 3 ICMs, all including ioversol and iomeprol. Six patients allergic to iopamidol tolerated ioversol and 1 tolerated iomeprol. Four patients allergic to ioversol and 1 allergic to iomeprol tolerated iopamidol. The global reaction rate was 0.2%, differing for each ICM (iopamidol, 0.14%; ioversol, 0.2%; and iomeprol, 0.4%; P < .001). Positive skin test results were found in a low percentage of patients in whom skin test-based CCT identified an alternative non-cross-reactive ICM. Low-grade cross-reactivity was found, especially between iopamidol and ioversol. Reactions were more severe in patients with positive skin test results. The reaction rate was greater for iomeprol compared with iopamidol (reaction rate, 2.8%) and ioversol (reaction rate, 2%).
This study identified a possible underlying specific IgE-mediated mechanism by positive skin test result in a low percentage of patients with IHRs to ICMs. In these patients, the CCT based on skin test results was useful for identifying an alternative non-cross-reactive ICM. More studies are needed to investigate the underlying mechanism in patients with IHRs and negative skin test results.
对碘化造影剂(ICM)的速发型超敏反应(IHR)仍是临床常见问题。在某些情况下,皮肤试验和嗜碱性粒细胞活化试验结果呈阳性提示存在特异性IgE介导机制。皮肤试验和对照激发试验(CCT)有助于管理这些患者。
研究西班牙一家三级医院7年间IHRs对ICM的临床和过敏特征。
记录反应的人口统计学和临床数据。在西班牙马德里格雷戈里奥·马拉尼翁大学综合医院过敏科接受治疗的患者进行皮肤试验。结果呈阳性的患者,用另一种皮肤试验阴性的ICM进行CCT。计算每种ICM的总体反应率并进行比较。
329例患者共发生342次反应。皮肤症状最为常见(87.7%)。共有196例患者接受了过敏检查,其中15例(7.6%)皮肤试验结果呈阳性。皮肤试验结果呈阳性的患者反应比阴性患者更严重(1级,46.7%对73.6%;2级,33.3%对20.9%;3级,20%对5.46%;P<.05)。3例患者对3种ICM有交叉反应,均包括碘海醇和碘美普尔。6例对碘帕醇过敏的患者耐受碘海醇,1例耐受碘美普尔。4例对碘海醇过敏和1例对碘美普尔过敏的患者耐受碘帕醇。总体反应率为0.2%,每种ICM有所不同(碘帕醇,0.14%;碘海醇,0.2%;碘美普尔,0.4%;P<.001)。在基于皮肤试验的CCT确定了一种非交叉反应性替代ICM的患者中,皮肤试验结果呈阳性的比例较低。发现存在低度交叉反应,尤其是碘帕醇和碘海醇之间。皮肤试验结果呈阳性的患者反应更严重。碘美普尔的反应率高于碘帕醇(反应率为2.8%)和碘海醇(反应率为2%)。
本研究发现,在一小部分IHRs对ICM的患者中,皮肤试验结果呈阳性可能提示存在潜在的特异性IgE介导机制。对于这些患者,基于皮肤试验结果的CCT有助于确定一种非交叉反应性替代ICM。需要更多研究来调查IHRs且皮肤试验结果为阴性的患者的潜在机制。